ChemoRad nanoparticles: A novel multifunctional nanoparticle platform for targeted delivery of concurrent chemoradiation

Andrew Z. Wang; Kai Yuet; Liangfang Zhang; Frank X. Gu; Minh Huynh-Le; Aleksandar F. Radovic-Moreno; Philip W. Kantoff; Neil H. Bander; Robert Langer; Omid C. Farokhzad

doi:10.2217/nnm.10.6

ChemoRad nanoparticles: A novel multifunctional nanoparticle platform for targeted delivery of concurrent chemoradiation

Andrew Z. Wang, Kai Yuet, Liangfang Zhang, Frank X. Gu, Minh Huynh-Le, Aleksandar F. Radovic-Moreno, Philip W. Kantoff, Neil H. Bander, Robert Langer, Omid C. Farokhzad

Research output: Contribution to journal › Article › peer-review

102 Scopus citations

Abstract

Aim: The development of chemoradiation - the concurrent administration of chemotherapy and radiotherapy - has led to significant improvements in local tumor control and survival. However, it is limited by its high toxicity. In this study, we report the development of a novel NP (nanoparticle) therapeutic, ChemoRad NP, which can deliver biologically targeted chemoradiation. Method: A biodegradable and biocompatible lipid-polymer hybrid NP that is capable of delivering both chemotherapy and radiotherapy was formulated. Results: Using docetaxel, indium¹¹¹ and yttrium⁹⁰ as model drugs, we demonstrated that the ChemoRad NP can encapsulate chemotherapeutics (up to 9% of NP weight) and radiotherapeutics (100 mCi of radioisotope per gram of NP) efficiently and deliver both effectively. Using prostate cancer as a disease model, we demonstrated the targeted delivery of ChemoRad NPs and the higher therapeutic efficacy of ChemoRad NPs. Conclusion: We believe that the ChemoRad NP represents a new class of therapeutics that holds great potential to improve cancer treatment.

Original language	English (US)
Pages (from-to)	361-368
Number of pages	8
Journal	Nanomedicine
Volume	5
Issue number	3
DOIs	https://doi.org/10.2217/nnm.10.6
State	Published - Apr 2010
Externally published	Yes

Keywords

Biologically targeted nanoparticle
ChemoRad NP
Chemoradiation
Chemoradiation nanoparticle
Nanomedicine
Nanotechnology
Prostate cancer

ASJC Scopus subject areas

Bioengineering
Medicine (miscellaneous)
Biomedical Engineering
General Materials Science

Access to Document

10.2217/nnm.10.6

Cite this

@article{765bdaedf8ea45ad82293b2fae0650e8,

title = "ChemoRad nanoparticles: A novel multifunctional nanoparticle platform for targeted delivery of concurrent chemoradiation",

abstract = "Aim: The development of chemoradiation - the concurrent administration of chemotherapy and radiotherapy - has led to significant improvements in local tumor control and survival. However, it is limited by its high toxicity. In this study, we report the development of a novel NP (nanoparticle) therapeutic, ChemoRad NP, which can deliver biologically targeted chemoradiation. Method: A biodegradable and biocompatible lipid-polymer hybrid NP that is capable of delivering both chemotherapy and radiotherapy was formulated. Results: Using docetaxel, indium111 and yttrium90 as model drugs, we demonstrated that the ChemoRad NP can encapsulate chemotherapeutics (up to 9% of NP weight) and radiotherapeutics (100 mCi of radioisotope per gram of NP) efficiently and deliver both effectively. Using prostate cancer as a disease model, we demonstrated the targeted delivery of ChemoRad NPs and the higher therapeutic efficacy of ChemoRad NPs. Conclusion: We believe that the ChemoRad NP represents a new class of therapeutics that holds great potential to improve cancer treatment.",

keywords = "Biologically targeted nanoparticle, ChemoRad NP, Chemoradiation, Chemoradiation nanoparticle, Nanomedicine, Nanotechnology, Prostate cancer",

author = "Wang, {Andrew Z.} and Kai Yuet and Liangfang Zhang and Gu, {Frank X.} and Minh Huynh-Le and Radovic-Moreno, {Aleksandar F.} and Kantoff, {Philip W.} and Bander, {Neil H.} and Robert Langer and Farokhzad, {Omid C.}",

year = "2010",

month = apr,

doi = "10.2217/nnm.10.6",

language = "English (US)",

volume = "5",

pages = "361--368",

journal = "Nanomedicine",

issn = "1743-5889",

publisher = "Future Medicine Ltd.",

number = "3",

}

TY - JOUR

T1 - ChemoRad nanoparticles

T2 - A novel multifunctional nanoparticle platform for targeted delivery of concurrent chemoradiation

AU - Wang, Andrew Z.

AU - Yuet, Kai

AU - Zhang, Liangfang

AU - Gu, Frank X.

AU - Huynh-Le, Minh

AU - Radovic-Moreno, Aleksandar F.

AU - Kantoff, Philip W.

AU - Bander, Neil H.

AU - Langer, Robert

AU - Farokhzad, Omid C.

PY - 2010/4

Y1 - 2010/4

N2 - Aim: The development of chemoradiation - the concurrent administration of chemotherapy and radiotherapy - has led to significant improvements in local tumor control and survival. However, it is limited by its high toxicity. In this study, we report the development of a novel NP (nanoparticle) therapeutic, ChemoRad NP, which can deliver biologically targeted chemoradiation. Method: A biodegradable and biocompatible lipid-polymer hybrid NP that is capable of delivering both chemotherapy and radiotherapy was formulated. Results: Using docetaxel, indium111 and yttrium90 as model drugs, we demonstrated that the ChemoRad NP can encapsulate chemotherapeutics (up to 9% of NP weight) and radiotherapeutics (100 mCi of radioisotope per gram of NP) efficiently and deliver both effectively. Using prostate cancer as a disease model, we demonstrated the targeted delivery of ChemoRad NPs and the higher therapeutic efficacy of ChemoRad NPs. Conclusion: We believe that the ChemoRad NP represents a new class of therapeutics that holds great potential to improve cancer treatment.

AB - Aim: The development of chemoradiation - the concurrent administration of chemotherapy and radiotherapy - has led to significant improvements in local tumor control and survival. However, it is limited by its high toxicity. In this study, we report the development of a novel NP (nanoparticle) therapeutic, ChemoRad NP, which can deliver biologically targeted chemoradiation. Method: A biodegradable and biocompatible lipid-polymer hybrid NP that is capable of delivering both chemotherapy and radiotherapy was formulated. Results: Using docetaxel, indium111 and yttrium90 as model drugs, we demonstrated that the ChemoRad NP can encapsulate chemotherapeutics (up to 9% of NP weight) and radiotherapeutics (100 mCi of radioisotope per gram of NP) efficiently and deliver both effectively. Using prostate cancer as a disease model, we demonstrated the targeted delivery of ChemoRad NPs and the higher therapeutic efficacy of ChemoRad NPs. Conclusion: We believe that the ChemoRad NP represents a new class of therapeutics that holds great potential to improve cancer treatment.

KW - Biologically targeted nanoparticle

KW - ChemoRad NP

KW - Chemoradiation

KW - Chemoradiation nanoparticle

KW - Nanomedicine

KW - Nanotechnology

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=77951223396&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951223396&partnerID=8YFLogxK

U2 - 10.2217/nnm.10.6

DO - 10.2217/nnm.10.6

M3 - Article

C2 - 20394530

AN - SCOPUS:77951223396

SN - 1743-5889

VL - 5

SP - 361

EP - 368

JO - Nanomedicine

JF - Nanomedicine

IS - 3

ER -

ChemoRad nanoparticles: A novel multifunctional nanoparticle platform for targeted delivery of concurrent chemoradiation

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this